Southport Capital Management’s AstraZeneca AZN Stock Holding History

Southport Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-299	Closed	-$24K	–	191
2018 Q3	$24K	Buy	+299	New	+$22.6K	0.01%	326
2016 Q3	–	Sell	-299	Closed	-$18K	–	181
2016 Q2	$18K	Buy	+299	New	+$17.4K	0.01%	373

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Southport Capital Management's AZN Position: Q4 2018 in Review

Southport Capital Management sold out of AstraZeneca (AZN) in Q4 2018, closing a stake of 299 shares — an estimated $24K sold.

Southport Capital Management first reported a position in AZN in Q2 2016 and held it in 2 quarters. The position peaked at $24K in Q3 2018. 557 funds tracked by Wall St. Rank hold AZN as of Q4 2018.

Southport Capital Management reported no remaining AstraZeneca position as of Q4 2018 after selling out during the quarter.
Southport Capital Management sold 299 AstraZeneca shares in Q4 2018, an estimated $24K.
Southport Capital Management first reported a position in AstraZeneca in Q2 2016 and held it in 2 quarters.
Southport Capital Management's AstraZeneca position peaked at $24K in Q3 2018.
557 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2018.

Based on Southport Capital Management's 13F filing for Q4 2018, filed 18 Jan 2019.